Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00080585" target="_blank" >RIV/65269705:_____/25:00080585 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00140668
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0090825824011855" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0090825824011855</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ygyno.2024.10.028" target="_blank" >10.1016/j.ygyno.2024.10.028</a>
Alternative languages
Result language
angličtina
Original language name
Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer
Original language description
Objective. The prognostic relevance of hormonal biomarkers in endometrial cancer (EC) has been wellestablished. A refined three-tiered risk model for estrogen receptor (ER)/progesterone receptor (PR) expression was shown to improve prognostication. This has not been evaluated in relation to the molecular subgroups. This study aimed to evaluate the ER/PR expression within the molecular subgroups in EC. Methods. A retrospective multicenter cohort study was performed and data from the European Network for Individualized Treatment centers and Vancouver, Canada were used. ER/PR immunohistochemical expression was grouped as: ER/PR 0-10 %, 20-80 % or 90-100 %. Molecular subgroups were determined with full nextgeneration sequencing or combined with immunohistochemistry: POLEmut, mismatch repair deficient (MMRd), p53mut and no-specific molecular profile (NSMP). Results. A total of 739 patients were included (median follow-up 5.0 years). Tumors were classified as POLEmut in 9.1 %(N = 67), MMRd in 27.6 %(N = 204), p53mut in 20.8 %(N = 154) and NSMP in 42.5 %(N = 314). Among all molecular subgroups, patients with ER/PR 90-100 % expression revealed the best disease- specific survival (DSS). Within p53mut, PR 90-100 % expression showed a 5-year DSS of 100.0 %. ER expression is prognostic more relevant in MMRd and NSMP tumors while PR expression in p53mut and NSMP tumors. Across all molecular subgroups, PR 0-10 %, p53mut, lympho-vascular space invasion and FIGO stage III-IV remained independently prognostic for reduced DSS Whereas PR 90-100 % and POLEmut remained independently prognostic for improved DSS. Conclusion. We demonstrated that ER/PR expression remain prognostically relevant within the molecular subgroups, and that a three-tiered cutoff refines prognostication. These data support incorporating routine evaluation of ER/PR expression in clinical practice.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30214 - Obstetrics and gynaecology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Gynecologic Oncology
ISSN
0090-8258
e-ISSN
1095-6859
Volume of the periodical
192
Issue of the periodical within the volume
JAN 2025
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
15-23
UT code for WoS article
001355614100001
EID of the result in the Scopus database
2-s2.0-85208262427